MAPT and Alzheimer disease: In a Phase 1B randomized, placebo-controlled trial of the tau-targeting antisense oligonucleotide MAPTRx, MAPTRx exhibited a dose-dependent reduction in tau protein levels in patients with mild AD, with effects lasting for 24 weeks, indicating its potential therapeutic efficacy as a pathological biomarker [278].